Lack of radiosensitivity predicts poor disease specific survival in myxoid liposarcoma

Matthew T. Houdek, Katherine E. Mallett, Mark J. Heidenreich, Safia K. Ahmed, Doris E. Wenger, John Rudolph H. Smith, Brittany L. Siontis, Steven I. Robinson, Andrew L. Folpe, Ivy A. Petersen, Peter S. Rose

Research output: Contribution to journalArticlepeer-review


Background: Compared to other sarcomas, myxoid liposarcoma (ML) is known to be radiosensitive, with improved oncologic outcomes. Although these tumors “shrink” following radiotherapy, there is a paucity of data examining the degree of radiosensitivity and oncologic outcome. The purpose of the study was to evaluate pre- and postradiotherapy tumor volume to determine if size reduction impacts outcome. Methods: We reviewed 62 patients with ML undergoing surgical resection combined with preoperative radiotherapy, with pre- and postradiotherapy MRI. This included 34 (55%) males, with a mean age of 47 ± 14 years. All tumors were deep to the fascia, and 12 (19%) patients had tumors with a >5% round-cell component. Results: The mean volume reduction was 54% ± 29%. Compared to patients with >25% volume reduction, patients with reduction ≤25% had worse 10-year disease specific survival (86% vs. 37%, p < 0.01), in addition to an increased risk of metastatic disease (HR 4.63, p < 0.01) and death due to disease (HR 4.52, p < 0.01). Conclusion: Lack of volume reduction is a risk factor for metastatic disease and subsequent death due to disease in patients with extremity ML treated with combined preoperative radiotherapy and surgery. This data could be used to stratify patients for adjuvant therapies and follow-up intervals.

Original languageEnglish (US)
Pages (from-to)848-854
Number of pages7
JournalJournal of Surgical Oncology
Issue number5
StatePublished - Apr 2023


  • myxoid liposarcoma
  • outcome
  • radiotherapy
  • survival

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Lack of radiosensitivity predicts poor disease specific survival in myxoid liposarcoma'. Together they form a unique fingerprint.

Cite this